Ipamorelin

Ipamorelin is a linear pentapeptide with non-natural residues — α-aminoisobutyric acid at position 1 and D-amino acids at positions 3 and 4 — designed to confer enzymatic stability while retaining ghrelin-receptor affinity. The molecule engages the growth-hormone secretagogue receptor type 1a (GHS-R1a) and is documented in the literature for its narrow receptor-selectivity profile relative to earlier GHRPs, with comparatively limited engagement of corticotroph and lactotroph signaling. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance and a short systemic half-life under standard parenteral paradigms. Interaction profile in the literature centers on PLC/IP3 calcium signaling downstream of GHS-R1a activation. All activity descriptors here are framed as documented in published work. Structural confirmation is established by mass spectrometry molecular-ion match and HPLC-validated purity on each Certificate of Analysis.

Experimental domains documented in the published literature include GHS-R1a receptor-binding assays, structure-activity studies probing the role of D-amino-acid substitutions on receptor selectivity, somatotroph-cell calcium-signaling investigations, comparative work alongside other GHRP-class secretagogues, and feedback-loop modeling in growth-hormone-axis paradigms. Investigators have also characterized ipamorelin in studies of receptor internalization kinetics and in screening assays for GHS-R1a-selective ligands. Its use in laboratory research extends to mechanism-elucidation paradigms where the literature frames the pentapeptide as a tool for parsing GHS-R1a signaling from broader pituitary-axis effects. The reference standard is supplied for these and equivalent in-vitro experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature when designing context-specific protocols.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C38H49N9O5 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.